A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFR
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer harboring driver oncogene excepting EGFR
- Registration Number
- JPRN-UMIN000049022
- Lead Sponsor
- orth East Japan Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 870
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who are judged by the principal investigator or sub-investigator to be inappropriate for participation in this study. (2) Patients who had no driver mutation/translocation or EGFR mutation only.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method